Evidence map›Paper›PMID 29017454›Full record

ArticleBMC cancer2017

Productivity losses and public finance burden attributable to breast cancer in Poland, 2010-2014.

Błażej Łyszczarz, Ewelina Nojszewska

Abstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Are current Polish guidelines for prophylactic mastectomy sufficient?Hereditary cancer in clinical practice · 2026
    Review
  4. Paid and unpaid productivity losses across 28 European countries due to excess deaths and COVID-19 deaths from 2020 to 2023.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. A systemmatic literature review on indirect costs of women with breast cancer.Cost effectiveness and resource allocation : C/E · 2022
    Review
  11. The Direct and Indirect Costs of Breast Cancer in Poland: Estimates for 2017-2019.International journal of environmental research and public health · 2022
    Article
  12. Article
  13. Debt, Ownership, and Size: The Case of Hospitals in Poland.International journal of environmental research and public health · 2021
    Article
  14. Article
  15. Production Losses Associated with Alcohol-Attributable Mortality in the European Union.International journal of environmental research and public health · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Błażej ŁyszczarzDepartment of Public Health, Faculty of Health Sciences, Nicolaus Copernicus University in Toruń, ul, Sandomierska 16, 85-830, Bydgoszcz, Poland. blazej@cm.umk.pl.ORCID http://orcid.org/0000-0002-5825-5079
Ewelina NojszewskaDepartment of Appiled Economics, Collegium of Management and Finance, Warsaw School of Economics, ul. Madalińskiego 6/8, 02-513, Warszawa, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundApart from the health and social burden of the disease, breast cancer (BC) has important economic implications for the sick, health system and whole economy. There has been a growing interest in the economic aspects of breast cancer and analyses of the disease costs seem to be the most explored topic. However, the results from these studies are hardly comparable. With this study we aim to contribute to the field by providing estimates of productivity losses and public finance burden attributable to BC in Poland.

methodsWe used retrospective prevalence-based top-down approach to estimate the productivity losses (indirect costs) of BC in Poland in the period 2010-2014. Human capital method (HCM) and societal perspective were used to estimate the costs of: absenteeism of the sick and caregivers, presenteeism of the sick and caregivers, disability, and premature mortality. We also used figures illustrating public finance burden attributable to the disease. Deterministic sensitivity analysis was performed to assess the stability of the estimates. A variety of data sources were used with the social insurance system and Polish National Cancer Registry being the most important ones.

resultsProductivity losses associated with BC in Poland were €583.7 million in 2010 and they increased to €699.7 million in 2014. Throughout the period these costs accounted for 0.162-0.171% of GDP, an equivalent of 62,531-65,816 per capita GDP. Losses attributable to disability and premature mortality proved to be the major cost drivers with 27.6%-30.6% and 22.0%-24.6% of the total costs respectively. The costs due to caregivers' presenteeism were negligible (0.1% of total costs). Public finance expenditure for social insurance benefits to BC sufferers ranged from €50.2 million (2010) to €56.6 million (2014), an equivalent of 0.72-0.79% of expenditures for all diseases. Potential losses in public finance revenues accounted for €173.9 million in 2010 and €211.0 million in 2014. Sensitivity analysis showed that the results were robust to changes in the model parameters.

conclusionsThe productivity losses attributable to BC in Poland were a sizable burden for the society. They contributed both to decreased economy output and to public finance deficit.

Indexed as

AdultAgedBreast NeoplasmsCaregiversCost of IllnessEfficiencyFemaleHealth Care CostsHumansMiddle AgedPolandBreast cancerEconomic burdenHuman capital methodIndirect costsPolandProductivity lossesPublic finance

Identifiers

PMID29017454
PMCPMC5634844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.